Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC). Study objectives: Primary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (N

Trial Details

NCT ID
NCT05284552
Phase
PHASE2
Sponsor
University Hospital, Linkoeping
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Tinzaparin Injectable Solution
Locations (sample)
  • Eksjö, Eksjö, Sweden|57.66643,14.97205
  • Gothenburg, Gothenburg, Sweden|57.70716,11.96679
  • Jönköping, Jönköping County, Sweden|57.78145,14.15618
  • Linköping, Linköping, Sweden|58.41086,15.62157
  • Umeå, Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • The subject has given written consent to participate in the study.
  • Age 18 and above
  • Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or p…
  • Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →